Creo Medical Group PLC (AIM:CREO) was on a rip on Monday morning after announcing a significant step up in its European operations.
Its Speedboat Inject device has been given the green light for use in upper gastrointestinal (GI) procedures throughout the continent, a potential game-changer for patients suffering from a range of GI disorders such as achalasia, delayed gastric emptying, and Zenkers diverticulum.
Creo’s shares were seen 16.8% higher at 37.38p with a market capitalisation of £131mln as of midday, June 19.